The need for a strategic therapeutic approach: multiple sclerosis in check

被引:24
作者
Inojosa, Hernan [1 ]
Proschmann, Undine [1 ]
Akguen, Katja [1 ]
Ziemssen, Tjalf [1 ]
机构
[1] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Ctr Clin Neurosci, Dept Neurol, Fetscherstr 74, D-01307 Dresden, Germany
关键词
disease-modifying therapies; DMTs; multiple sclerosis; strategy; treatment; chess; INTRAMUSCULAR INTERFERON BETA-1A; LONG-TERM OUTCOMES; DISEASE-ACTIVITY; NO EVIDENCE; CONVERSION; TIME; NEUROLOGISTS; ASSOCIATION; DISABILITY; EVOLUTION;
D O I
10.1177/20406223211063032
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multiple sclerosis (MS) is the most common chronic autoimmune neurological disease. Its therapeutic management has drastically evolved in the recent years with the development of specific disease-modifying therapies (DMTs). Together with the established injectables, oral and intravenous alternatives are now available for MS patients with significant benefits to modulate the disease course. Certain drugs present with a higher efficacy than the others, profiles and frequencies of adverse events differentiate as well. Thus due to the several and different treatment alternatives, the therapeutic approach adopted by neurologists requires a tactical focus for a targeted, timed, and meaningful treatment decision. An integration of rational and emotional control with proper communication skills is necessary for shared decision-making with patients. In this perspective paper, we reinforce the necessary concept of strategic MS treatment approach using all available therapies based on scientific evidence and current experience. We apply a didactic analogy to the strategic game chess. The opening with oriented attack (i.e. already in early disease stages as clinical isolated syndrome), a correct choice of chess pieces to move (i.e. among the several DMTs), a re-assessment reaction to different scenarios (e.g. sustained disease activity, adverse events, and family planning) and the advantage of real-world data are discussed to try the best approach to ultimately successfully approach the best personalized MS treatment.
引用
收藏
页数:15
相关论文
共 74 条
[1]   Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis [J].
Armoiry, X. ;
Kan, A. ;
Melendez-Torres, G. J. ;
Court, R. ;
Sutcliffe, P. ;
Auguste, P. ;
Madan, J. ;
Counsell, C. ;
Clarke, A. .
JOURNAL OF NEUROLOGY, 2018, 265 (05) :999-1009
[2]   Interferon β-1a for early multiple sclerosis:: CHAMPS trial subgroup analyses [J].
Beck, RW ;
Chandler, DL ;
Cole, SR ;
Simon, JH ;
Jacobs, LD ;
Kinkel, RP ;
Selhorst, JB ;
Rose, JW ;
Cooper, JA ;
Rice, G ;
Murray, TJ ;
Sandrock, AW .
ANNALS OF NEUROLOGY, 2002, 51 (04) :481-490
[3]   Neurologists The Last Bedside Physician-Scientists [J].
Berger, Joseph R. .
JAMA NEUROLOGY, 2013, 70 (08) :965-966
[4]   Treatment of Acute Relapses in Multiple Sclerosis [J].
Berkovich, Regina .
NEUROTHERAPEUTICS, 2013, 10 (01) :97-105
[5]   Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis [J].
Brown, J. William L. ;
Coles, Alasdair ;
Horakova, Dana ;
Havrdova, Eva ;
Izquierdo, Guillermo ;
Prat, Alexandre ;
Girard, Marc ;
Duquette, Pierre ;
Trojano, Maria ;
Lugaresi, Alessandra ;
Bergamaschi, Roberto ;
Grammond, Pierre ;
Alroughani, Raed ;
Hupperts, Raymond ;
McCombe, Pamela ;
Van Pesch, Vincent ;
Sola, Patrizia ;
Ferraro, Diana ;
Grand'Maison, Francois ;
Terzi, Murat ;
Lechner-Scott, Jeannette ;
Flechter, Schlomo ;
Slee, Mark ;
Shaygannejad, Vahid ;
Pucci, Eugenio ;
Granella, Franco ;
Jokubaitis, Vilija ;
Willis, Mark ;
Rice, Claire ;
Scolding, Neil ;
Wilkins, Alastair ;
Pearson, Owen R. ;
Ziemssen, Tjalf ;
Hutchinson, Michael ;
Harding, Katharine ;
Jones, Joanne ;
McGuigan, Christopher ;
Butzkueven, Helmut ;
Kalincik, Tomas ;
Robertson, Neil ;
Onofrj, Marco ;
De Luca, Giovanna ;
Di Tommaso, Valeria ;
Travaglini, Daniela ;
Pietrolongo, Erika ;
di Ioia, Maria ;
Farina, Deborah ;
Mancinelli, Luca ;
Hodgkinson, Suzanne ;
Oreja-Guevara, Celia .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (02) :175-187
[6]   Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis [J].
Brownlee, Wallace J. ;
Altmann, Dan R. ;
Prados, Ferran ;
Miszkiel, Katherine A. ;
Eshaghi, Arman ;
Wheeler-Kingshott, Claudia A. M. Gandini ;
Barkhof, Frederik ;
Ciccarelli, Olga .
BRAIN, 2019, 142 :2276-2287
[7]   Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS [J].
Capra, Ruggero ;
Cordioli, Cinzia ;
Rasia, Sarah ;
Gallo, Fabio ;
Signori, Alessio ;
Sormani, Maria Pia .
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (13) :1757-1761
[8]  
Chataway Jeremy, 2018, Lancet Neurol, V17, P118, DOI 10.1016/S1474-4422(17)30463-5
[9]   Corticosteroids for the long-term treatment in multiple sclerosis [J].
Ciccone, A. ;
Beretta, S. ;
Brusaferri, F. ;
Galea, I ;
Protti, A. ;
Spreafico, C. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (01)
[10]   The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses [J].
Claflin, Suzi B. ;
Broadley, Simon ;
Taylor, Bruce V. .
FRONTIERS IN NEUROLOGY, 2019, 9